Journal of Clinical Oncology, Vol 14, 3056-3061, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

GJ Creemers, G Bolis, M Gore, G Scarfone, AJ Lacave, JP Guastalla, R Despax, G Favalli, R Kreinberg, S Van Belle, I Hudson, J Verweij and WW Ten Bokkel Huinink
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek), The Netherlands.

PURPOSE: Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen. PATIENTS AND METHODS: Topotecan 1.5 mg/m2/d was administered intravenously by 30-minute infusion for 5 days repeated every 3 weeks. As the cisplatin-free interval relates to response in subsequent treatment, patients were stratified in subgroups, ie, cisplatin- refractory, cisplatin-resistant, and cisplatin-sensitive. RESULTS: One- hundred eleven patients entered the study. Nineteen patients were considered to be ineligible; 92 patients were assessable for response. A total of 552 courses were given (median, four per patient; range, one to 17). The major toxicities were leukocytopenia and neutropenia, which were grade 3 to 4 in 54.2% and 69.1% of courses, respectively, but with only 4.3% of these being grade 4 neutropenia plus fever or infectious complications. Prophylactic granulocyte colony-stimulating factor (G- CSF) was given in 20.5% of courses to maintain dose-intensity. Other relatively frequent side effects were alopecia (82%), nausea (36.4%), and vomiting (17.5%). The overall response rate was 16.3%, with one complete response (CR) and 14 partial responses (PRs). In the cisplatin- refractory, cisplatin-resistant, and cisplatin-sensitive strata, the response rates were 5.9%, 17.8%, and 26.7%, respectively. The median duration of time of documented response was 21.7 weeks (range, 4.6 to 41.9). CONCLUSION: Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer. Further investigations of topotecan in ovarian cancer, including first-line use and combination with other active agents, are indicated.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. J. Hoskins Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy J. Clin. Oncol., March 20, 2009; 27(9): 1355 - 1358. [Full Text] [PDF]

				J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al. Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182. [Abstract] [Full Text] [PDF]

				M. Markman New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer Oncologist, February 1, 2007; 12(2): 186 - 190. [Abstract] [Full Text] [PDF]

				U Seifart, T Fink, C Schade-Brittinger, K Hans, C Mueller, G Koschel, H Schroeder, R Lorenz, J Dethling, and M Wolf Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 104 - 109. [Abstract] [Full Text] [PDF]

				S. Joffe and F. G. Miller Rethinking Risk-Benefit Assessment for Phase I Cancer Trials J. Clin. Oncol., July 1, 2006; 24(19): 2987 - 2990. [Full Text] [PDF]

				D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis Oncologist, October 1, 2005; 10(9): 686 - 694. [Abstract] [Full Text] [PDF]

				D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919. [Abstract] [Full Text] [PDF]

				G. G. Dark, A. H. Calvert, R. Grimshaw, C. Poole, K. Swenerton, S. Kaye, R. Coleman, G. Jayson, T. Le, S. Ellard, et al. Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., March 20, 2005; 23(9): 1859 - 1866. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				A. Iop, A. M. Manfredi, and S. Bonura Fatigue in cancer patients receiving chemotherapy: an analysis of published studies Ann. Onc., May 1, 2004; 15(5): 712 - 720. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity Oncologist, February 1, 2004; 9(1): 33 - 42. [Abstract] [Full Text] [PDF]

				H. Hochster, E. R. Plimack, C. D. Runowicz, J. Speyer, R. C. Wallach, J. Sorich, J. Mandeli, S. Wadler, J. Wright, and F. M. Muggia Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group J. Clin. Oncol., January 1, 2004; 22(1): 120 - 126. [Abstract] [Full Text] [PDF]

				W. ten Bokkel Huinink, S. R. Lane, and G. A. Ross Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma Ann. Onc., January 1, 2004; 15(1): 100 - 103. [Abstract] [Full Text] [PDF]

				M. Agrawal and E. J. Emanuel Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data JAMA, August 27, 2003; 290(8): 1075 - 1082. [Abstract] [Full Text] [PDF]

				M. A. Bookman Developmental Chemotherapy and Management of Recurrent Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167. [Abstract] [Full Text] [PDF]

				J. Sehouli, D. Stengel, G. Oskay, O. Camara, H.-J. Hindenburg, P. Klare, J. Blohmer, G. Heinrich, D. Elling, P. Ledwon, et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy Ann. Onc., November 1, 2002; 13(11): 1749 - 1755. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Novel Therapies in Ovarian Cancer Management: An Update on the Role of Topotecan Oncologist, October 1, 2002; 7(90005): 1 - 2. [Full Text] [PDF]

				T. J. Herzog Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 3 - 10. [Abstract] [Full Text] [PDF]

				D. K. Armstrong Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease Oncologist, October 1, 2002; 7(90005): 20 - 28. [Abstract] [Full Text] [PDF]

				R. Morris and A. Munkarah Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 29 - 35. [Abstract] [Full Text] [PDF]

				R. L. Coleman Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary Oncologist, October 1, 2002; 7(90005): 46 - 55. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky Weekly Topotecan: An Alternative to Topotecan's Standard Daily x 5 Schedule? Oncologist, August 1, 2002; 7(4): 324 - 330. [Abstract] [Full Text] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				V. Dieras, P. Bougnoux, T. Petit, P. Chollet, P. Beuzeboc, C. Borel, F. Husseini, A. Goupil, P. Kerbrat, J. L. Misset, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin {+/-} taxane-pretreated ovarian cancer patients Ann. Onc., February 20, 2002; 13(2): 258 - 266. [Abstract] [Full Text] [PDF]

				D. L. Clarke-Pearson, L. Van Le, T. Iveson, C. W. Whitney, P. Hanjani, G. Kristensen, J. H. Malfetano, R. A. Beckman, G. A. Ross, S. R. Lane, et al. Oral Topotecan as Single-Agent Second-Line Chemotherapy in Patients With Advanced Ovarian Cancer J. Clin. Oncol., October 1, 2001; 19(19): 3967 - 3975. [Abstract] [Full Text]

				A. Bowman, T. Rye, G. Ross, A. Wheatley, and J. F. Smyth Effective Dosing of Topotecan With Carboplatin in Relapsed Ovarian Cancer: A Phase I/II Study J. Clin. Oncol., July 1, 2001; 19(13): 3255 - 3259. [Abstract] [Full Text] [PDF]

				M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.-F. Heron, G. Bolis, H. Malmstrom, et al. Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer J. Clin. Oncol., April 1, 2001; 19(7): 1893 - 1900. [Abstract] [Full Text] [PDF]

				J. von Pawel, U. Gatzemeier, J.-L. Pujol, L. Moreau, S. Bildat, M. Ranson, G. Richardson, C. Steppert, A. Riviere, I. Camlett, et al. Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2001; 19(6): 1743 - 1749. [Abstract] [Full Text] [PDF]

				M. E. Royce, P. M. Hoff, P. Dumas, Y. Lassere, J. J. Lee, J. Coyle, M. P. Ducharme, R. De Jager, and R. Pazdur Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog J. Clin. Oncol., March 1, 2001; 19(5): 1493 - 1500. [Abstract] [Full Text] [PDF]

				D. R.A. Mans, A. B. da Rocha, and G. Schwartsmann Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Anti-Cancer Compounds Oncologist, June 1, 2000; 5(3): 185 - 198. [Abstract] [Full Text]

				M. J. A. de Jonge, W. J. Loos, H. Gelderblom, A. S. Th. Planting, M. E. L. van der Burg, A. Sparreboom, E. Brouwer, V. van Beurden, M. A. Mantel, E. Doyle, et al. Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects J. Clin. Oncol., May 10, 2000; 18(10): 2104 - 2115. [Abstract] [Full Text] [PDF]

				G. J. S. Rustin, A. E. Nelstrop, S. M. Bentzen, S. J. Bond, and P. McClean Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials J. Clin. Oncol., April 1, 2000; 18(8): 1733 - 1739. [Abstract] [Full Text] [PDF]

				M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al. Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202. [Abstract] [Full Text] [PDF]

				M. Markman and M. A. Bookman Second-Line Treatment of Ovarian Cancer Oncologist, February 1, 2000; 5(1): 26 - 35. [Abstract] [Full Text]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				H. Hochster, S. Wadler, C. Runowicz, L. Liebes, H. Cohen, R. Wallach, J. Sorich, B. Taubes, and J. Speyer Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy J. Clin. Oncol., August 1, 1999; 17(8): 2553 - 2553. [Abstract] [Full Text] [PDF]

				N. G. Avgeropoulos and T. T. Batchelor New Treatment Strategies for Malignant Gliomas Oncologist, June 1, 1999; 4(3): 209 - 224. [Abstract] [Full Text]

				M. A. Bookman Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy Oncologist, April 1, 1999; 4(2): 87 - 94. [Abstract] [Full Text]

				S. A. Cannistra Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited J. Clin. Oncol., March 1, 1999; 17(3): 741 - 741. [Full Text] [PDF]

				J.-F. Héron Topotecan: An Oncologist's View Oncologist, December 1, 1998; 3(6): 390 - 402. [Abstract] [Full Text]

				D. Armstrong and S. O'Reilly Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity Oncologist, February 1, 1998; 3(1): 4 - 10. [Abstract] [Full Text]

				V. Relias and J. Andrew Skirvin Review : Topoisomerase I inhibitors: 1. Topotecan Journal of Oncology Pharmacy Practice, December 1, 1997; 3(4): 173 - 185. [Abstract] [PDF]